Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OTR4132
- Development stage
- Unknown
- Lead developer
- OTR3
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Intravenous, Intracerebroventricular
01
Overview
OTR4132 is a synthetic heparan sulfate glycosaminoglycan mimetic and member of the RGTA (ReGeneraTing Agents) family. It is a dextran-based biopolymer designed to protect and stabilize endogenous heparin-binding growth factors from proteolytic degradation, thereby enabling tissue repair and neuroprotection. Preclinical studies demonstrate that OTR4132 exerts neuroprotective effects in models of central nervous system injury, attenuating cholinergic neuron degeneration after partial immunotoxic lesions and promoting functional recovery. OTR4132 can cross the blood-brain barrier and accumulate in lesion sites, where it restores the extracellular matrix, enhances brain plasticity, and supports processes like neurogenesis and angiogenesis. Currently, OTR4132 is in clinical evaluation for acute ischemic stroke following thrombectomy, with phase 2 trials underway to confirm efficacy and safety.
- Brand names
- OTR4132-MDOTR-4132-MDOTR 4132-MD
- Other names
- RGTA OTR4132synthetic glycosaminoglycan mimetic OTR4132
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))
Beyond the preview
Go deeper on OTR4132.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OTR4132.